SFC Capital

Novai Ltd is a British biotechnology company founded in 2019 and headquartered in Reading, United Kingdom. It commercialises DARC Technology, a patented exploratory retinal biomarker that combines a biologic agent with an artificial‑intelligence algorithm to detect cellular‑level disease activity using standard imaging equipment. DARC is approved by the FDA and MHRA for use in clinical studies of age‑related macular degeneration and glaucoma, and it can identify responders and non‑responders to therapies, enabling the creation of enriched patient cohorts and reducing the cost of ineffective treatments. The platform also offers real‑time, single‑cell visualization for eye and brain disease research, and further indications such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, diabetes and cancer are under investigation.

Chiron offers a revolutionary approach to managing chronic illnesses. Based on the user's profile, it uses AI to suggest tailored self-care treatments that have the highest chance of success. It then offers a straightforward framework for evaluating the results.

LaennecAI is a clinical AI company specializing in chronic disease management solutions. It has developed a medical device, a digital stethoscope, which transforms modern smartphones into powerful diagnostic tools. The company's technology enables precise monitoring and analysis of respiratory and cardiac sounds, facilitating telemedicine, remote patient monitoring, and virtual wards. This ensures patients receive in-depth, reliable analysis and continuous care.

Reneural develops innovative, accessible technologies focused on improving cardiovascular disease treatment and management. Their flagship product is a wearable smart medical system designed to prevent blood clots in lower limbs, usable both clinically and at home.

Llusern Scientific operates molecular point-of-care testing centers, focusing on urinary tract infection diagnostics. Their innovative technology rapidly detects and identifies bacteria, empowering medical professionals to make prompt decisions and enhance patient care.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

Medwise.ai operates a customizable search platform that uses natural language processing and artificial intelligence technologies to provide clinical decision support for doctors. Its real-world data offers insights to various healthcare stakeholders, enabling doctors to organize medical knowledge and enhance patient care outcomes.

Vesynta is a medical technology company that specializes in individualizing drug therapy through its innovative blood monitoring platform. The company’s technology integrates drug monitoring hardware with precision dosing software to create a universal bedside platform aimed at evidence-based clinical decision support. By utilizing robotic automation, analytical software, and machine learning, Vesynta's system determines a patient's drug exposure, empowering healthcare providers to make data-driven decisions. This approach facilitates the personalization of drug dosages, ultimately enhancing treatment outcomes while minimizing side effects for patients.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

NIQS Technology is a spin-out from the University of Leeds specializing in innovative quantum glucose management solutions aimed at transforming diabetes care. The company has developed a patented, non-invasive glucose monitoring technology that employs a contact-based wearable device made of nano-engineered glass. This device mimics the optical properties of glucose, allowing for continuous, accurate glucose level monitoring without the need for needles or blood sampling. By providing accessible and user-friendly monitoring solutions, NIQS Technology seeks to empower individuals living with diabetes to manage their condition more effectively and improve their overall quality of life, while minimizing the risk of complications associated with traditional glucose management methods.

Llusern Scientific operates molecular point-of-care testing centers, focusing on urinary tract infection diagnostics. Their innovative technology rapidly detects and identifies bacteria, empowering medical professionals to make prompt decisions and enhance patient care.

PulmoBioMed is a company focused on providing innovative solutions for clinicians and researchers through non-invasive sampling of fluids. The firm has developed a passive fluid aerosol sampler designed to capture exhaled breath condensate and aerosol samples. This product effectively segregates exhaled and environmental particles by size, addressing critical challenges such as sample contamination and loss. PulmoBioMed's technology aims to generate highly reproducible data with precise digital molecular analysis, facilitating the study of biological agents and supporting metabolomic profiling. Through its advancements, the company seeks to enhance research capabilities and improve patient outcomes in the field of respiratory health.

Elaitra develops AI-driven breast cancer diagnostic tools. Their platform includes a voice-based patient engagement system powered by Generative LLM and an AI reading tool for 3D X-rays, approved by FDA and UK regulators.

MedQ is a smart platform that helps healthcare professionals complete assessments using a three-step process: Select-Send-Analyse. It is designed for clinics to transition from paper assessments to remote patient monitoring.

Medwise.ai operates a customizable search platform that uses natural language processing and artificial intelligence technologies to provide clinical decision support for doctors. Its real-world data offers insights to various healthcare stakeholders, enabling doctors to organize medical knowledge and enhance patient care outcomes.

Novai Ltd is a British biotechnology company founded in 2019 and headquartered in Reading, United Kingdom. It commercialises DARC Technology, a patented exploratory retinal biomarker that combines a biologic agent with an artificial‑intelligence algorithm to detect cellular‑level disease activity using standard imaging equipment. DARC is approved by the FDA and MHRA for use in clinical studies of age‑related macular degeneration and glaucoma, and it can identify responders and non‑responders to therapies, enabling the creation of enriched patient cohorts and reducing the cost of ineffective treatments. The platform also offers real‑time, single‑cell visualization for eye and brain disease research, and further indications such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, diabetes and cancer are under investigation.

NIQS Technology is a spin-out from the University of Leeds specializing in innovative quantum glucose management solutions aimed at transforming diabetes care. The company has developed a patented, non-invasive glucose monitoring technology that employs a contact-based wearable device made of nano-engineered glass. This device mimics the optical properties of glucose, allowing for continuous, accurate glucose level monitoring without the need for needles or blood sampling. By providing accessible and user-friendly monitoring solutions, NIQS Technology seeks to empower individuals living with diabetes to manage their condition more effectively and improve their overall quality of life, while minimizing the risk of complications associated with traditional glucose management methods.

PolyMetrix focuses on developing biometric data processing technology for the construction and healthcare sectors. It also removes demographic bias with an automated data processing pipeline and captures human facial, hand, and foot data through Ai to ensure employee safety. PolyMetrix was founded in 2021 and was headquartered in London.

Founded by specialists in nanotechnology, medicinal chemistry, and artificial intelligence, Nanovery aims to enable early detection of cancer through a rapid and affordable blood test. Its core technology involves AI-powered nanorobots that capture circulating tumor DNA and emit a fluorescent signal for point-of-care detection.

Hormona is a pioneering femtech company dedicated to improving women's hormonal health. It offers home testing kits for accurate, pain-free hormone monitoring, supported by leading medical experts. The results seamlessly integrate with the Hormona app, empowering women to understand and manage their hormones effectively.

Hormona is a pioneering femtech company dedicated to improving women's hormonal health. It offers home testing kits for accurate, pain-free hormone monitoring, supported by leading medical experts. The results seamlessly integrate with the Hormona app, empowering women to understand and manage their hormones effectively.

Elaitra develops AI-driven breast cancer diagnostic tools. Their platform includes a voice-based patient engagement system powered by Generative LLM and an AI reading tool for 3D X-rays, approved by FDA and UK regulators.

Novai Ltd is a British biotechnology company founded in 2019 and headquartered in Reading, United Kingdom. It commercialises DARC Technology, a patented exploratory retinal biomarker that combines a biologic agent with an artificial‑intelligence algorithm to detect cellular‑level disease activity using standard imaging equipment. DARC is approved by the FDA and MHRA for use in clinical studies of age‑related macular degeneration and glaucoma, and it can identify responders and non‑responders to therapies, enabling the creation of enriched patient cohorts and reducing the cost of ineffective treatments. The platform also offers real‑time, single‑cell visualization for eye and brain disease research, and further indications such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, diabetes and cancer are under investigation.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

Founded by specialists in nanotechnology, medicinal chemistry, and artificial intelligence, Nanovery aims to enable early detection of cancer through a rapid and affordable blood test. Its core technology involves AI-powered nanorobots that capture circulating tumor DNA and emit a fluorescent signal for point-of-care detection.

Novai Ltd is a British biotechnology company founded in 2019 and headquartered in Reading, United Kingdom. It commercialises DARC Technology, a patented exploratory retinal biomarker that combines a biologic agent with an artificial‑intelligence algorithm to detect cellular‑level disease activity using standard imaging equipment. DARC is approved by the FDA and MHRA for use in clinical studies of age‑related macular degeneration and glaucoma, and it can identify responders and non‑responders to therapies, enabling the creation of enriched patient cohorts and reducing the cost of ineffective treatments. The platform also offers real‑time, single‑cell visualization for eye and brain disease research, and further indications such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, diabetes and cancer are under investigation.

Medwise.ai operates a customizable search platform that uses natural language processing and artificial intelligence technologies to provide clinical decision support for doctors. Its real-world data offers insights to various healthcare stakeholders, enabling doctors to organize medical knowledge and enhance patient care outcomes.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

Novai Ltd is a British biotechnology company founded in 2019 and headquartered in Reading, United Kingdom. It commercialises DARC Technology, a patented exploratory retinal biomarker that combines a biologic agent with an artificial‑intelligence algorithm to detect cellular‑level disease activity using standard imaging equipment. DARC is approved by the FDA and MHRA for use in clinical studies of age‑related macular degeneration and glaucoma, and it can identify responders and non‑responders to therapies, enabling the creation of enriched patient cohorts and reducing the cost of ineffective treatments. The platform also offers real‑time, single‑cell visualization for eye and brain disease research, and further indications such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, diabetes and cancer are under investigation.

CircaGene Ltd is a London-based company that specializes in bioinformatics and genetic testing services. Established in 2018, it offers a direct-to-consumer platform where individuals can order personal DNA tests while ensuring privacy through patented end-to-end encryption. The company provides actionable insights from DNA analysis to help users identify hereditary health risks, improve their lifestyle, and make informed health decisions. CircaGene's platform features user-friendly reports and connects consumers with advanced genetic research algorithms, facilitating access to comprehensive healthcare resources. By prioritizing genetic privacy and security, CircaGene aims to empower individuals to take proactive measures in managing their health and well-being.

Algocyte is a UK-based company that specializes in providing comprehensive, medically-driven solutions for remote blood testing and health monitoring. The company enables healthcare professionals to remotely track and assess patients with various conditions, including cancer, anemia, and autoimmune disorders. Algocyte's innovative medical device conducts a wide range of hematological and biochemical tests, allowing for continuous health monitoring. By analyzing collected data over time, Algocyte generates detailed health profiles that offer a more accurate understanding of an individual's health status compared to traditional single-snapshot assessments.

Medtech

Whiterabbit.ai develops software that uses artificial intelligence to detect cancer at the earliest stages. The company offers an AI-driven platform designed to redefine breast cancer screening and diagnosis, addressing the entire screening process from patient engagement to clinician decision support. The platform aims to improve patient compliance, enhance provider accuracy, and accelerate cancer detection in radiology by delivering targeted technology that supports medical professionals and elevates the overall quality of care.

ORB Innovations is a deep tech digital health company that provides a platform for high-quality biometric data and insights to support healthier and higher-performing lives. It develops ORB Sport, a smart mouthguard that monitors head movements and forces during sports using accelerometers, a gyroscope, and a magnetometer. The device delivers detailed reports to help athletes track injuries, prevent misdiagnoses, and optimize recovery, combining wearable technology with data analytics to inform performance and wellbeing decisions.

Curamicus Ltd is a healthcare technology company based in Polegate, United Kingdom, founded in 2015. Formerly known as Hip Buddy Ltd, the company specializes in developing wearable devices that utilize sensors, artificial intelligence, and cloud technology to identify anxiety and vulnerability in elderly individuals. By creating massively scalable assistive technology, Curamicus aims to enhance the quality of life for elders and vulnerable populations, enabling them to live safer and more fulfilling lives. The focus of Curamicus is on personalized wellness solutions that effectively manage anxiety and improve overall well-being for its users.

Jupiter Diagnostics is a company that specializes in innovative blood testing solutions utilizing patented nano crystal labeled technology. This technology allows for the rapid processing of multiple blood tests from a simple finger prick, delivering results within 10 minutes and at a cost significantly lower than traditional laboratory testing. By providing high-quality and affordable diagnostics, Jupiter Diagnostics aims to enhance the accessibility of medical testing for both clinicians and patients. Their intuitive testing process simplifies blood sample collection, facilitating quicker decision-making for healthcare practitioners and ultimately improving patient care.

Bioepic Limited, founded in 2014 and based in Hereford, United Kingdom, specializes in integrating natural supplements with mobile technology to enhance health monitoring. The company has developed a unique software platform that combines food and drink supplements with smartphone applications, allowing users to track their health improvements effectively. By transforming smartphones into medical-grade health monitors, Bioepic enables individuals to continuously assess key indicators of their body chemistry. This innovative approach empowers fitness enthusiasts and health-conscious individuals to make informed decisions about their wellbeing and performance.

Rocking the tea world with a range of vitamin enriched super green teas.

FindMe Health is an online platform designed to empower patients by providing access to reliable and comparable information on the quality and pricing of healthcare services. Targeting individuals who are seeking alternatives to NHS treatment, especially when they are ineligible or facing long waiting times, the platform allows users to compare hospital consultants based on various criteria such as procedure volume, patient feedback, hospital location, and treatment costs. This comprehensive comparison helps patients make informed decisions regarding their healthcare options. In addition to offering detailed insights on conditions, hospitals, and consultants, FindMe Health facilitates the booking of initial consultations directly through the site. By consolidating essential information in one place, it aims to simplify the often confusing landscape of self-pay healthcare and enable patients to take control of their health decisions.

Performr.ai is a Biotechnology Research firm offering monitoring and body sensors for personalised health and insights.

Eupnoos is a health-tech company specializing in digital lung health solutions. It offers smartphone-based, automated lung function testing and data interpretation for various devices and telehealth platforms.